erasee2015-05-05 00:03
$ Juno Therapeutics (JUNO)$ $Kite Pharma(KITE)$ $Bellicum Pharmaceuticals (BLCM)$ $BLUEBIRD BIO INC(BLUE)$ $诺华(NVS)$ $强生(JNJ)$ $ZIOPHARM Oncology(ZIOP)$ $INTREXON CORP(XON)$ $ADRO(ADRO)$查看全文
$Intrexon(XON)$ 8-K Current report, items 2.01, 5.03, 8.01, and 9.01 Accession Number: 0001193125-20-023400 Act: 34 Size: 392 KB 网页链接
$Intrexon(XON)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-20-005705 Act: 34 Size: 120 KB 网页链接
$Intrexon(XON)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001193125-20-007429 Act: 34 Size: 12 MB 网页链接
$Intrexon(XON)$ 内部交易: 2020-01-06,CFO,Sterling Rick L. ,卖出,6533普通股, $5.83
$Intrexon(XON)$ 内部交易: 2020-01-06,总裁 and CEO,Sabzevari Helen ,卖出,6732普通股, $5.83
$Intrexon(XON)$ 内部交易: 2020-01-06,Chief Science Officer,Reed Thomas D. ,卖出,5416普通股, $5.83
$Intrexon(XON)$ 内部交易: 2020-01-06,SVP, IP Affairs,Perez Jeffrey Thomas ,卖出,6533普通股, $5.83
$Intrexon(XON)$ 内部交易: 2020-01-06,Chief Legal Officer,Lehr Donald P. ,卖出,7155普通股, $5.83
$Intrexon(XON)$ 内部交易: 2020-01-06,COO,Bostick Thomas ,卖出,6533普通股, $5.83
$Intrexon(XON)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001567619-20-000727 Size: 29 KB 网页链接